This interactive session gives you the opportunity to be part of the discussion, share your ideas and hear from your peers on their thoughts.

Among the key talking points to consider:

• Debating whether a standardized definition of PPF is needed across clinical trials and regulatory frameworks
• Exploring how different progression criteria influence trial enrolment, patient selection, and interpretation of treatment efficacy
• Discussing how a harmonized framework could accelerate drug development and improve comparability across PPF studies